JP6832336B2 - アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用 - Google Patents

アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用 Download PDF

Info

Publication number
JP6832336B2
JP6832336B2 JP2018502356A JP2018502356A JP6832336B2 JP 6832336 B2 JP6832336 B2 JP 6832336B2 JP 2018502356 A JP2018502356 A JP 2018502356A JP 2018502356 A JP2018502356 A JP 2018502356A JP 6832336 B2 JP6832336 B2 JP 6832336B2
Authority
JP
Japan
Prior art keywords
formula
compound
alcohol
acget61
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018502356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523644A (ja
JP2018523644A5 (enExample
Inventor
ロベルト カチャグリア
ロベルト カチャグリア
アントネッラ ロシェ
アントネッラ ロシェ
Original Assignee
ラボラトリオ ファルマセウティコ シー．ティ．ソシエタ ア レスポンサビリタ リミタータ
ラボラトリオ ファルマセウティコ シー．ティ．ソシエタ ア レスポンサビリタ リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトリオ ファルマセウティコ シー．ティ．ソシエタ ア レスポンサビリタ リミタータ, ラボラトリオ ファルマセウティコ シー．ティ．ソシエタ ア レスポンサビリタ リミタータ filed Critical ラボラトリオ ファルマセウティコ シー．ティ．ソシエタ ア レスポンサビリタ リミタータ
Publication of JP2018523644A publication Critical patent/JP2018523644A/ja
Publication of JP2018523644A5 publication Critical patent/JP2018523644A5/ja
Application granted granted Critical
Publication of JP6832336B2 publication Critical patent/JP6832336B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018502356A 2015-08-04 2016-08-03 アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用 Expired - Fee Related JP6832336B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102015000041820 2015-08-04
ITUB2015A002860A ITUB20152860A1 (it) 2015-08-04 2015-08-04 Selezionata amide dell?acido ?-idrossibutirrico e suoi usi nel trattamento dell?abuso da alcool
PCT/EP2016/068517 WO2017021438A1 (en) 2015-08-04 2016-08-03 SELECTED AMIDE OF γ -HYDROXYBUTYRIC ACID AND USES THEREOF IN THE TREATMENT OF ALCOHOL MISUSE

Publications (3)

Publication Number Publication Date
JP2018523644A JP2018523644A (ja) 2018-08-23
JP2018523644A5 JP2018523644A5 (enExample) 2019-08-15
JP6832336B2 true JP6832336B2 (ja) 2021-02-24

Family

ID=54542363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502356A Expired - Fee Related JP6832336B2 (ja) 2015-08-04 2016-08-03 アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用

Country Status (24)

Country Link
US (1) US10336687B2 (enExample)
EP (1) EP3331853B1 (enExample)
JP (1) JP6832336B2 (enExample)
KR (1) KR102817897B1 (enExample)
CN (1) CN108026029B (enExample)
AU (1) AU2016302869B2 (enExample)
CA (1) CA2994599C (enExample)
CL (1) CL2018000282A1 (enExample)
CO (1) CO2018002428A2 (enExample)
DK (1) DK3331853T3 (enExample)
EA (1) EA033769B9 (enExample)
ES (1) ES2776628T3 (enExample)
GE (1) GEP20207107B (enExample)
IL (1) IL257314B (enExample)
IT (1) ITUB20152860A1 (enExample)
MX (1) MX2018001239A (enExample)
MY (1) MY185942A (enExample)
PH (1) PH12018550008A1 (enExample)
PL (1) PL3331853T3 (enExample)
PT (1) PT3331853T (enExample)
SM (1) SMT202000337T1 (enExample)
UA (1) UA121994C2 (enExample)
WO (1) WO2017021438A1 (enExample)
ZA (1) ZA201801402B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US12201612B2 (en) 2017-07-31 2025-01-21 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
CN113185403A (zh) * 2021-07-02 2021-07-30 山东国邦药业有限公司 一种甲醚制备环丙胺中间体环丙甲酸甲酯的方法
WO2023126076A1 (en) * 2022-01-03 2023-07-06 Laboratorio Farmaceutico C.T. S.R.L. Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283782B1 (it) * 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo

Also Published As

Publication number Publication date
CA2994599C (en) 2023-08-29
GEP20207107B (en) 2020-05-11
KR20180066033A (ko) 2018-06-18
AU2016302869B2 (en) 2020-10-22
CN108026029B (zh) 2020-12-04
WO2017021438A1 (en) 2017-02-09
CN108026029A (zh) 2018-05-11
BR112018002245A2 (pt) 2018-09-18
IL257314B (en) 2020-04-30
EA033769B9 (ru) 2020-04-10
PL3331853T3 (pl) 2020-06-15
US20180230086A1 (en) 2018-08-16
IL257314A (en) 2018-03-29
DK3331853T3 (da) 2020-03-16
CL2018000282A1 (es) 2018-07-13
EA033769B1 (ru) 2019-11-22
GEAP202014717A (en) 2020-01-27
SMT202000337T1 (it) 2020-07-08
ZA201801402B (en) 2019-01-30
PH12018550008A1 (en) 2018-07-09
JP2018523644A (ja) 2018-08-23
PT3331853T (pt) 2020-02-25
UA121994C2 (uk) 2020-08-25
EP3331853B1 (en) 2019-12-11
CA2994599A1 (en) 2017-02-09
KR102817897B1 (ko) 2025-06-05
MY185942A (en) 2021-06-14
MX2018001239A (es) 2018-07-06
CO2018002428A2 (es) 2018-07-10
EA201890419A1 (ru) 2018-07-31
AU2016302869A1 (en) 2018-03-15
US10336687B2 (en) 2019-07-02
ITUB20152860A1 (it) 2017-02-04
EP3331853A1 (en) 2018-06-13
ES2776628T3 (es) 2020-07-31

Similar Documents

Publication Publication Date Title
EP1908753B1 (en) Novel heterocyclidene acetamide derivative
JP2007505111A (ja) 非沈静ａ−２アゴニスト１−（２，３−ジメチル−フェニル）−エチル−１、３−ジヒドロ−イミダゾール−２−チオン
JP6832336B2 (ja) アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用
TWI774683B (zh) sGC刺激劑之固體形式
US20220096444A1 (en) Prophylactic or therapeutic agent for delirium
US9643971B2 (en) Breathing control modulating compounds, and methods of using same
WO2011133212A1 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
AU5287499A (en) Use of (S)(-)-amisulpride for the manufacture of a medicament for the treatment of positive, negative, affective or cognitive symptoms of Schizophrenia
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
AU2022339672B2 (en) Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph
JP5792318B2 (ja) ブロムフェナク有機塩、ならびにその製造方法、組成物および使用
US11858908B2 (en) Compositions and methods for inhibiting IDO1
US20230339854A1 (en) Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
WO2017011445A1 (en) Heteroaryl carbonitriles for the treatment of disease
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
HK40000275A (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
BR112018002245B1 (pt) Composto amida selecionado do ácido ?-hidroxybutírico, processo para a preparação do referido composto, uso do referido composto e composição farmacêutica compreendendo o referido composto
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210201

R150 Certificate of patent or registration of utility model

Ref document number: 6832336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees